Sacroccocygeal teratoma in a female newborn with clinical features of trisomy 13: a case report from Central Africa

Toni Kasole Lubala¹,²
Olivier Mukuku¹
Mick Pongombo Shongo¹,²
Augustin Mulangu Mutombo¹
Nina Lubala¹
Oscar Numbi Luboya¹
Prosper Lukusa-Tshilobo³
¹Department of Paediatrics, Faculty of Medicine, ²Center for Human Genetics, Faculty of Medicine, University of Lubumbashi, Lubumbashi, ³Department of Paediatrics and Centre for Human Genetics, University Hospital, University of Kinshasa, Kinshasa, Democratic Republic of Congo

Introduction: The objective of this report is to describe the first patient presenting clinical features of trisomy 13 in association with a sacrococcygeal teratoma.

Case presentation: We present the case of a Congolese female infant born with bilateral cleft lip and palate, hypotelorism, microcephaly, and capillary hemangioma on her face. She presented with a large sacrococcygeal mass (15.0 cm × 12.0 cm × 5.0 cm) with a cystic consistency and a positive transillumination.

Conclusion: This observation suggests that overexpression of certain genes on chromosome 13 may lead to tumor formation from remnant cells of Hensen’s node.

Keywords: Patau syndrome, Hensens’ Node, sacrococcygeal, teratoma

Introduction
Sacrococcygeal teratoma is a rare tumor with a birth prevalence of 1 in 21,700 births.¹ In a relatively large proportion (20%), this tumor can have a malignant development, most commonly a papillary adenocarcinoma.² Previously, teratome of the liver, umbilical cord, and oral region have been described in three patients with trisomy 13 syndrome (Patau syndrome), but thus far, no sacrococcygeal teratoma has been observed in this syndrome. Trisomy 13 has an incidence of 1 in 10,000–20,000 with variable expression and is characterized by the clinical triad of cleft lip and palate, microphthalmia/anophthalmia, and postaxial polydactyly.³ However, other anomalies are frequently associated.⁴,⁵ The objective of this report is to describe a Congolese newborn presenting with a sacrococcygeal teratoma and the clinical features of trisomy 13.

Case presentation
A female patient was born in Fungurume (mining area in southern Katanga Province, Democratic Republic of Congo) at 40 weeks of gestation via lower segment cesarean section delivery with a birth weight of 4,580 g (+2.48 standard deviation [SD], World Health Organization [WHO] growth charts 2006)⁶ and a length of 51 cm (0.9 SD, WHO growth charts 2006). Her mother was 40 years old and her father 51 years old, both were healthy and unrelated. The mother did not use medications during pregnancy. No prenatal ultrasound scan was performed. She was referred on day 2. On clinical examination, we noted a bilateral cleft lip and palate, hypotelorism, microcephaly (28 cm, −5.06 SD, WHO growth charts), and postaxial polydactyly on her face. No scalp defect has been observed. The infant had low-set ears and a short neck (Figure 1). No organized ocular tissues could be seen or palpated. The infant had five normal fingers
Since comparative genomic hybridization array and karyotyping are not available in this part of the world, the diagnosis of trisomy 13 in this patient relied on clinical grounds. Two signs of the characteristic clinical triad were present in our patient (cleft lip and palate and microphthalmia/anophthalmia), but no postaxial polydactyly has been observed. Table 1 shows clinical features in trisomy 13 with molecular confirmation versus our patient. As we can see in Table 1 as well as in Caba et al’s paper, full classical triad of trisomy 13 is not constant, which is an indirect evidence supporting the argument that our patient likely had trisomy 13.

Whereas in most industrialized countries, trisomy 13 is diagnosed prenatally, ∼24% of pregnant women have no access to prenatal care services, and the vast majority of them currently do not have access to prenatal ultrasound follow-up in the Democratic Republic of Congo. The identification of cell-free DNA in maternal blood and the recent development of polymerase chain reaction-based noninvasive DNA hold enormous promise for diagnosis of fetal trisomies 21, 18, and 13 in general pregnant populations. However, the lack of teaching, and thus interest and knowledge, in human genetics might be barriers to this testing in Democratic Republic of Congo.

Upon reviewing the literature, the relationship of aneuploidy and chromosomal instability to neoplasia has been discussed over the past decades. Three patients with trisomy 13 disorders have been reported with teratoma. In Dische and Gardner’s paper, a fetus with trisomy 13 syndrome and teratomas of liver and neck has been described. Yapar et al have presented a case of epignathus (oral cavity teratoma) detected prenatally in a fetus with trisomy 13 syndrome. More recently, an unusual solid and cystic mass was diagnosed at 17 weeks fetus with trisomy 13. Fetopathological examination revealed an umbilical cord teratoma. These three cases suggest the association between trisomy 13 and teratoma. However, the mechanism of origin of these tumors is probably not the same. Extragonadal teratomas are thought to arise from germ cells that migrate aberrantly during embryogenesis, whereas sacrococcygeal teratoma is believed to arise from totipotent cells derived from the remnant of Hensen’s node located in the coccyx region, the caudal eminence.

As we can see in Table 2, sacrococcygeal teratoma has already been described in some chromosomal disorders syndrome such as partial trisomy 1q, partial trisomy 3q, and mosaic r (21), and genomic gain in 1q and 12p has been observed in sacrococcygeal teratoma. Furthermore, it has been shown that some genes in individuals with trisomy 21 may inhibit the generation and growth of tumors originating from the remnant of Hensen’s node.
Table 1 Clinical features in trisomy 13 with molecular confirmation versus our patient

<table>
<thead>
<tr>
<th>Studies</th>
<th>Year</th>
<th>Country</th>
<th>Samples (N)</th>
<th>Features</th>
<th>Craniofacial</th>
<th>Thorax/abdomen</th>
<th>Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patau et al (Publication princeps)</td>
<td>1960</td>
<td>USA</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al</td>
<td>2007</td>
<td>Taiwan</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Petry et al</td>
<td>2013</td>
<td>Brazil</td>
<td>30</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quelin et al</td>
<td>2014</td>
<td>France</td>
<td>3</td>
<td></td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mbui-Musanzayi et al</td>
<td>2014</td>
<td>Democratic Republic of Congo</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient</td>
<td>2014</td>
<td>Democratic Republic of Congo</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Overview of reported teratoma in patients with chromosomal disorder syndromes

<table>
<thead>
<tr>
<th>Chromosomal disorder</th>
<th>Localization</th>
<th>Study</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy 13</td>
<td>Liver and neck</td>
<td>Dische and Gardiner</td>
<td>1978</td>
</tr>
<tr>
<td>Trisomy 12</td>
<td>Ovarian</td>
<td>López Ginés et al</td>
<td>1989</td>
</tr>
<tr>
<td>Trisomy 1q and 19p</td>
<td>Facial</td>
<td>Schwartz et al</td>
<td>1992</td>
</tr>
<tr>
<td>Trisomy 13</td>
<td>Oral</td>
<td>Yapor et al</td>
<td>1995</td>
</tr>
<tr>
<td>Trisomy 3</td>
<td>Ovarian</td>
<td>Mertens et al</td>
<td>1998</td>
</tr>
<tr>
<td>Tetrasomy 1q</td>
<td>Oral</td>
<td>Scheres et al</td>
<td>1999</td>
</tr>
<tr>
<td>Trisomy 1q</td>
<td>Sacrococcygeal</td>
<td>Wax et al</td>
<td>2000</td>
</tr>
<tr>
<td>Monosomy 7/trisomy 2p</td>
<td>Sacrococcygeal</td>
<td>Le cagne et al</td>
<td>2003</td>
</tr>
<tr>
<td>Trisomy 13</td>
<td>Umbilical cord</td>
<td>Hargitai et al</td>
<td>2005</td>
</tr>
<tr>
<td>Trisomy 10/monosomy 17p</td>
<td>Sacrococcygeal</td>
<td>Batukan et al</td>
<td>2007</td>
</tr>
<tr>
<td>Trisomy 3q</td>
<td>Sacrococcygeal</td>
<td>Dundur et al</td>
<td>2011</td>
</tr>
</tbody>
</table>

Trisomies as a gain-of-function mechanism by selection of a gain-of-function mutation or by gene dosage have been also implicated in hematologic malignancies as well as solid tumors through duplication and amplification of mutated alleles (RUNX1 or MET oncogene). It is not excluded that this represents a chance of association of two pathogenetically unrelated conditions, and the lack of genetic testing is a weakness of this report. Alternatively, given the previous reports of sacral appendage and teratomas with other localizations (Table 2) in other patient with trisomy 13, it is not excluded that overexpression of certain genes on chromosome 13 may lead to tumor formation from remnant cells of Hensen's node.

Consent
Written informed consent was obtained from the patient's legal guardians for publication of this case report and any accompanying images. The Hôpital Général De Référence de Kamalondo Ethics Committee advised ethical approval was not required.

Acknowledgment
The authors are grateful to the parents of the reported infant for their kind collaboration.
Author contributions
All authors were responsible for the study conception, data retrieval, and drafting the manuscript. All authors read and approved the final manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References